Financial results: Bioxyne; Rua Bioscience; Bod Science; Avecho; Wellnex Life; MGC Pharma; Cannasouth by Steve Jones March 7, 2024March 7, 2024 Bioxyne was hit with an impairment charge of A$11.5 million in the first half of FY24 […]
Cann Group vows to ‘vigorously’ defend Rua claims as contract dispute goes legal by Steve Jones February 16, 2024November 25, 2024
Company news: Bioxyne/BLS; Wellnex Life; Elixinol Wellness; Althea; Health House; Rua Bioscience by Steve Jones and Martin Lane February 7, 2024November 25, 2024
Company news: Rua Bioscience; IDT Australia; Emyria; Elixinol Wellness; Neurotech; Hygrovest; Releaf Group/ICCM; Botanix by Martin Lane August 30, 2023April 30, 2024
Company news: MedReleaf; Vitura Health; MGC Pharma; Rua Bioscience by Martin Lane April 13, 2023April 30, 2024
Rua Bioscience vows to continue product supply despite taking axe to local manufacturing by Steve Jones March 27, 2023April 30, 2024
Company news: Bod; Incannex; Medlab; Rua Bioscience; Emyria by Martin Lane October 20, 2022April 29, 2024
Company news: Cann Group; Cronos; Releaf Group; Rua Bioscience; Incannex by Martin Lane October 12, 2022April 29, 2024
Financial results: Avecho; AusCann; Zelira; Elixinol; Cann Group; Incannex; Creso Pharma; Medlab; Rua Bioscience by Steve Jones and Martin Lane September 1, 2022April 29, 2024
